Janssen’s Esketamine Needs Better Defined REMS, US FDA Panel Says
Executive Summary
Advisory committee overwhelmingly endorses approval for patients with treatment-resistant depression but says proposed Risk Evaluation and Mitigation Strategy needs refinement, including clarifying the types of facilities where the drug will be administered.
You may also be interested in...
J&J’s Esketamine: A Model “Breakthrough” Program For US FDA
J&J’s treatment-resistant depression drug esketamine had an easy time at an FDA advisory committee despite raising some tough regulatory questions. If you are looking for a showcase of how “Breakthrough” drug development collaboration can help a new therapy get to patients faster, this might be it.
Keeping Track: Accelerated Approval For Tecentriq And A Burst Of Filings And Submissions
The latest drug development news and highlights from our US FDA Performance Tracker.
Janssen’s Spravato Enters US Market With Enhanced REMS And Plans For A Monotherapy Trial
Restrictive risk management plan for antidepressant nasal spray requires patients be monitored for two hours after dosing and enroll in a patient registry; Janssen has agreed to conduct a monotherapy efficacy trial as a postmarketing commitment.